Also known as [D-Ala2]-dermorphin
A potent, highly selective μ-opioid heptapeptide from amphibian skin — a research tool containing a D-amino acid.
Research refreshed
Dermorphin is a naturally occurring heptapeptide first isolated from the skin of South American Phyllomedusa frogs. It is a potent and highly selective agonist at the μ-opioid receptor, several times more potent than morphine by weight in animal assays, and it is notable biochemically for containing a D-amino acid (D-alanine at position 2) — one of the few vertebrate peptides to do so, which is what protects it from rapid enzymatic breakdown. It is used as a pharmacological research tool; it is a controlled-interest opioid compound and is not an approved medicine.
Dermorphin is one of the classic examples of a vertebrate peptide that breaks the all-L rule: its second residue is D-alanine, incorporated post-translationally. That single stereochemical change makes the peptide resistant to the enzymes that would otherwise clear an opioid peptide quickly, and it is a textbook case for why D-amino acids matter in peptide design.
Pharmacologically it is a potent, selective μ-opioid agonist and is studied as a probe of opioid-receptor function and of peptide analgesia. Because it is a strong opioid, it is a research reagent rather than a wellness compound, and it has no approved therapeutic use. This page is a research and educational reference only.
High-affinity, selective μ-opioid-receptor agonism. The D-Ala2 residue and C-terminal amide confer resistance to peptidases, extending activity relative to all-L opioid peptides.
Behind every vial of Dermorphin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Dermorphin, specifically, is brought into being.
On paper, Dermorphin is C40H50N8O10 — about 803.9 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Dermorphin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Dermorphin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Dermorphin proves itself: identity confirmed by mass spectrometry against its ~803.9 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Dermorphin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A heptapeptide amide whose defining synthetic feature is a D-alanine at position 2 — built by solid-phase synthesis with an Fmoc-D-Ala building block and a C-terminal amide from Rink-amide resin. The D-residue is what resists peptidases; over a seven-residue chain, deletion-sequence removal sets the purity, and identity work must confirm the D-configuration rather than assume the all-L sequence.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Dermorphin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A heptapeptide from amphibian skin that is a potent, selective μ-opioid-receptor agonist, used as a research tool. It contains a rare D-amino acid (D-Ala2).
The D-alanine at position 2 resists enzymatic breakdown, which both extends the peptide’s activity and makes it a classic example of D-amino-acid stabilization in peptide design.
No — it is a potent opioid studied as a research reagent, with no approved therapeutic use.
No. This page is a research and educational reference, not medical advice.
Synthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.
ViewA natural brain / CNS peptide complex (Cytomax A-1) — the extract-based counterpart to Pinealon, targeting neuronal tissue.
ViewRussian synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.